{
  "id": 3930103,
  "title": "STAT+: In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs",
  "url": "https://urgent.news/2026/08/28/stat-in-autopsy-of-failed-heart-disease-study-astrazeneca-raises",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-28T09:23:13.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/08/28/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam/"
  },
  "original_language": "en",
  "account": "On Friday, AstraZeneca disclosed the unexpected failure of a high-profile heart disease clinical trial, revealing that its experimental drug, a type of silencer, provided no additional benefits for patients who were already on a stabilizer, a different class of medication. The study found that patients with ATTR-CM, a progressive condition, who received AstraZeneca’s drug, a silencer, experienced no improvement if they were already taking a stabilizer, an effect so significant that it led to the entire Phase 3 study’s failure. At the start of the trial, most participants were already taking a stabilizer. The trial’s outcome has far-reaching implications not just for AstraZeneca and its partnership with Ionis Pharmaceuticals, but for other companies that sell ATTR-CM drugs, including Alnylam Pharmaceuticals, which offers another silencer, and BridgeBio, the manufacturer of a new stabilizer. Analysts have suggested that the study’s results support the view that stabilizers, oral medications, may be superior to injectable silencers.",
  "summary": "AstraZeneca detailed the surprise failure of a closely watched heart disease trial, a study with ripple effects for a competitive billion-dollar market.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}